Central noradrenergic neurotoxicity of DSP4 in mice. Studies on the neuroprotective potential of the poly(ADP-ribose) polymerase inhibitor, benzamide

Central noradrenergic lesion induced by DSP-4 impairs the acquisition of avoidance reactions and prevents molecular changes in the amygdala

The noradrenergic system plays and an important modulatory role in memory consolidation of emotionally arousing tasks. However, the molecular cascades regulated in the brain by norepinephrine and involved in memory formation are still largely unknown. The purpose of the present study was to evaluate the role of the noradrenergic system on the acquisition of a highly emotionally arousing task-two-way active avoidance training-and its molecular and cellular substrates. The selective norepinephrine neurotoxin N-(2-chloroethyl)-N-ethyl-2 bromobenzylamine (DSP-4, 50mg/kg) was used. DSP-4-treated rats were trained in a shuttle box to avoid a footshock signaled by an auditory stimulus. Immunohistochemical mapping of the neuronal plasticity-related molecules c-Fos protein and the activated form of extracellular signal-regulated kinase (phosphorylated ERK [pERK]) was then employed. We found that DSP-4 treatment depleted the expression of the norepinephrine marker dopamine -hydroxylase (DBH) in the locus coeruleus and its projection area, the basolateral nucleus of the amygdala, confirming locus coeruleus noradrenergic lesion in the experimental animals. Furthermore, DSP-4 treatment impaired the acquisition of the avoidance reaction. We also found that acquisition of the active avoidance reaction induced c-Fos expression and ERK activation in the amygdala and piriform cortex. This upregulation was prevented by DSP-4 treatment. Thus, our data suggest that the noradrenergic system is involved in the acquisition of the active avoidance reaction by regulating ERK pathway activity and c-Fos expression in the amygdala and piriform cortex.

Noradrenergic mechanisms in neurodegenerative diseases: a theory

A deficiency in the noradrenergic system of the brain, originating largely from cells in the locus coeruleus (LC), is theorized to play a critical role in the progression of a family of neurodegenerative disorders that includes Parkinson's disease (PD) and Alzheimer's disease (AD). Consideration is given here to evidence that several neurodegenerative diseases and syndromes share common elements, including profound LC cell loss, and may in fact be different manifestations of a common pathophysiological process. Findings in animal models of PD indicate that the modification of LC-noradrenergic activity alters electrophysiological, neurochemical and behavioral indices of neurotransmission in the nigrostriatal dopaminergic system, and influences the response of this system to experimental lesions. In models related to AD, noradrenergic mechanisms appear to play important roles in modulating the activity of the basalocortical cholinergic system and its response to injury, and to modify cognitive functions including memory and attention. Mechanisms by which noradrenaline may protect or promote recovery from neural damage are reviewed, including effects on neuroplasticity, neurotrophic factors, neurogenesis, inflammation, cellular energy metabolism and excitotoxicity, and oxidative stress. Based on evidence for facilitatory effects on transmitter release, motor function, memory, neuroprotection and recovery of function after brain injury, a rationale for the potential of noradrenergic-based approaches, specifically alpha2-adrenoceptor antagonists, in the treatment of central neurodegenerative diseases is presented.

The toxicity of tumor necrosis factor-alpha upon cholinergic neurons within the nucleus basalis and the role of norepinephrine in the regulation of inflammation: implications for Alzheimer's disease

Inflammation and reduced forebrain norepinephrine are features of Alzheimer's disease that may interact to contribute to the degeneration of specific neural systems. We reproduced these conditions within the basal forebrain cholinergic system, a region that is vulnerable to degeneration in Alzheimer's disease. Tumor necrosis factor-alpha was infused into the basal forebrain of young mice pretreated with a norepinephrine neuronal toxin, N-(2-chloroethyl)-N-ethyl-2 bromobenzylamine (DSP4), with the expectation that the loss of noradrenergic input would enhance the loss of cholinergic neurons. The results indicate that chronic infusion of tumor necrosis factor-alpha alone significantly decreased cortical choline acetyltransferase activity and increased the number of activated microglia and astrocytes within the basal forebrain. The loss of forebrain norepinephrine following systemic treatment with DSP4 did not alter the level of cortical choline acetyltransferase activity or activate microglia but significantly activated astrocytes within the basal forebrain. Infusion of tumor necrosis factor-alpha into DSP4-pretreated mice also reduced cortical choline acetyltransferase activity on the side of the infusion; however, the decline was not significantly greater than that produced by the infusion of tumor necrosis factor-alpha alone. The neurodegeneration seen may be indirect since a double-immunofluorescence investigation did not find evidence for the co-existence of tumor necrosis factor-alpha type I receptors on choline acetyltransferase-positive cells in the basal forebrain. The results suggest that noradrenergic cell loss in Alzheimer's disease does not augment the consequences of the chronic neuroinflammation and does not enhance neurodegeneration of forebrain cholinergic neurons.